NCT07111988View on ClinicalTrials.gov

Valbenazine in Obsessive Compulsive Disorder

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

October 31, 2027

Study Completion Date

October 31, 2027

Conditions

Obsessive-Compulsive Disorder

Interventions

DRUG

Valbenazine

Selective vesicular monoamine transporter 2 (VMAT2) inhibitor

DRUG

Placebo

Pill that contains no medicine

Sponsors

Collaborators (1)

Neurocrine Biosciences

All Listed Sponsors

collaborator

Neurocrine Biosciences

INDUSTRY

lead

University of Chicago

OTHER